Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Qiagen ( (QGEN) ).
Qiagen N.V. has disclosed that the Dutch financial markets regulator AFM notified the company of a substantial shareholding in Qiagen held by Massachusetts Financial Services Company and related entities. According to the AFM register, these investors together hold a capital interest of 7.77% and voting rights amounting to 10.03% in Qiagen, split between direct and indirect holdings in ordinary shares. Qiagen emphasized that it is not responsible for the accuracy of the AFM notification, which nonetheless underscores a significant institutional investor position in the company’s shareholder base and may be viewed as an indication of ongoing interest from large asset managers in the stock.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, the Netherlands, is a life sciences and molecular diagnostics company whose shares are listed on major European exchanges including Frankfurt as well as on the NYSE and Swiss markets. The company develops and supplies sample and assay technologies used in molecular testing, serving clinical diagnostics, pharmaceutical and biotechnology companies, and research institutions worldwide.
Average Trading Volume: 1,196,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.81B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.